Logo image of VTVT

VTV THERAPEUTICS INC- CL A (VTVT) Stock Overview

USA - NASDAQ:VTVT - US9183852048 - Common Stock

24.1 USD
+0.97 (+4.19%)
Last: 10/3/2025, 8:11:28 PM

VTVT Key Statistics, Chart & Performance

Key Statistics
52 Week High26.99
52 Week Low12.62
Market Cap76.88M
Shares3.19M
Float1.69M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.12
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO07-30 2015-07-30
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


VTVT short term performance overview.The bars show the price performance of VTVT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

VTVT long term performance overview.The bars show the price performance of VTVT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 60

The current stock price of VTVT is 24.1 USD. In the past month the price increased by 31.62%. In the past year, price increased by 65.18%.

VTV THERAPEUTICS INC- CL A / VTVT Daily stock chart

VTVT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 22.09 413.22B
AMGN AMGEN INC 13.66 160.37B
GILD GILEAD SCIENCES INC 14.56 139.83B
VRTX VERTEX PHARMACEUTICALS INC 23.81 103.40B
REGN REGENERON PHARMACEUTICALS 13.15 63.59B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.82B
ARGX ARGENX SE - ADR 86.3 48.96B
ONC BEONE MEDICINES LTD-ADR 6.01 37.77B
INSM INSMED INC N/A 33.22B
BNTX BIONTECH SE-ADR N/A 25.36B
BIIB BIOGEN INC 9.99 23.44B
NTRA NATERA INC N/A 22.97B

About VTVT

Company Profile

VTVT logo image vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 23 full-time employees. The company went IPO on 2015-07-30. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Company Info

VTV THERAPEUTICS INC- CL A

3980 Premier Dr, Suite 310

High Point NORTH CAROLINA 27265 US

CEO: Stephen L. Holcombe

Employees: 23

VTVT Company Website

VTVT Investor Relations

Phone: 13368410300

VTV THERAPEUTICS INC- CL A / VTVT FAQ

What is the stock price of VTV THERAPEUTICS INC- CL A today?

The current stock price of VTVT is 24.1 USD. The price increased by 4.19% in the last trading session.


What is the ticker symbol for VTV THERAPEUTICS INC- CL A stock?

The exchange symbol of VTV THERAPEUTICS INC- CL A is VTVT and it is listed on the Nasdaq exchange.


On which exchange is VTVT stock listed?

VTVT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VTV THERAPEUTICS INC- CL A stock?

8 analysts have analysed VTVT and the average price target is 36.21 USD. This implies a price increase of 50.25% is expected in the next year compared to the current price of 24.1. Check the VTV THERAPEUTICS INC- CL A stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VTV THERAPEUTICS INC- CL A worth?

VTV THERAPEUTICS INC- CL A (VTVT) has a market capitalization of 76.88M USD. This makes VTVT a Micro Cap stock.


How many employees does VTV THERAPEUTICS INC- CL A have?

VTV THERAPEUTICS INC- CL A (VTVT) currently has 23 employees.


What are the support and resistance levels for VTV THERAPEUTICS INC- CL A (VTVT) stock?

VTV THERAPEUTICS INC- CL A (VTVT) has a support level at 14.57. Check the full technical report for a detailed analysis of VTVT support and resistance levels.


Is VTV THERAPEUTICS INC- CL A (VTVT) expected to grow?

The Revenue of VTV THERAPEUTICS INC- CL A (VTVT) is expected to decline by -100% in the next year. Check the estimates tab for more information on the VTVT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VTV THERAPEUTICS INC- CL A (VTVT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VTV THERAPEUTICS INC- CL A (VTVT) stock pay dividends?

VTVT does not pay a dividend.


When does VTV THERAPEUTICS INC- CL A (VTVT) report earnings?

VTV THERAPEUTICS INC- CL A (VTVT) will report earnings on 2025-11-10.


What is the Price/Earnings (PE) ratio of VTV THERAPEUTICS INC- CL A (VTVT)?

VTV THERAPEUTICS INC- CL A (VTVT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.12).


What is the Short Interest ratio of VTV THERAPEUTICS INC- CL A (VTVT) stock?

The outstanding short interest for VTV THERAPEUTICS INC- CL A (VTVT) is 1.01% of its float. Check the ownership tab for more information on the VTVT short interest.


VTVT Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to VTVT. When comparing the yearly performance of all stocks, VTVT is one of the better performing stocks in the market, outperforming 92.86% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VTVT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to VTVT. VTVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VTVT Financial Highlights

Over the last trailing twelve months VTVT reported a non-GAAP Earnings per Share(EPS) of -3.12. The EPS increased by 13.93% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -73.94%
ROE -708%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-13.48%
Sales Q2Q%N/A
EPS 1Y (TTM)13.93%
Revenue 1Y (TTM)-98.3%

VTVT Forecast & Estimates

8 analysts have analysed VTVT and the average price target is 36.21 USD. This implies a price increase of 50.25% is expected in the next year compared to the current price of 24.1.

For the next year, analysts expect an EPS growth of 0.14% and a revenue growth -100% for VTVT


Analysts
Analysts82.5
Price Target36.21 (50.25%)
EPS Next Y0.14%
Revenue Next Year-100%

VTVT Ownership

Ownership
Inst Owners39.63%
Ins Owners0.63%
Short Float %1.01%
Short Ratio4.41